Health Trials

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

Participants needed: 52
Trial details
Phase: Phase 1, Phase 2Age: 15-50Biological sex: AllType: InterventionalSponsor: Cellectis S.A.Updated: Sep 9, 2025Locations: 19
Eligibility criteria

B-ALL blast cells expressing CD22 [+2]

Read more
Status: Recruiting

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).

Participants needed: 80
Trial details
Phase: Phase 1, Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Cellectis S.A.Updated: Aug 24, 2025Locations: 10
Eligibility criteria

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 [+7]

Prior use of an investigational product (except for cell or gene therapies and M... [+20]

Read more